Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 659-669
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.659
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.659
Table 3 Sensitivity of the Glyco-model in detecting patients with pancreatic ductal adenocarcinoma of different stages
Subgroup | Sensitivity |
Overall | 84.95% (79/93) |
Stage I | 89.66% (26/29) |
Stage II | 77.27% (17/22) |
Stage III & IV | 90.00% (18/20) |
Unknown | 81.82% (18/22) |
- Citation: Wen YR, Lin XW, Zhou YW, Xu L, Zhang JL, Chen CY, He J. N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer. World J Gastrointest Oncol 2024; 16(3): 659-669
- URL: https://www.wjgnet.com/1948-5204/full/v16/i3/659.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i3.659